This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed PubMed Citation Articles by SoRelle, R.

(Circulation. 2002;106:e9035.)
© 2002 American Heart Association, Inc.

Cardiovascular News

Ruth SoRelle, MPH

Circulation Newswriter

An extract of the first 250 words of the full text is provided, because this article has no abstract.

CURE Works Patients With Acute Coronary Syndromes at All Risk Levels

When 12 562 patients who arrived at the hospital within 24 hours of the onset of symptoms of acute coronary syndrome were randomized to receive either clopidogrel or placebo in addition to aspirin for 3 to 12 months, the so-called "super aspirin" appeared to reduce risk consistently across risk groups, according to a report in this week’s issue of Circulation (Circulation. 2002;106:1622–1626).

According to researchers led by Andrzej Budaj, MD, of the Postgraduate Medical School at Growchowski Hospital in Warsaw, Poland, the original Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial showed that clopidogrel given soon after the cardiac event and continued long-term was superior to placebo in preventing recurrent events in patients with non–ST elevation acute coronary syndromes who were also receiving aspirin.

In this study, patients were stratified into risk groups according to the Thrombolysis in Myocardiac Infarction (TIMI) risk score. "The treatment effect of clopidogrel demonstrated in CURE was consistent in all categories of risk," the authors wrote. "However, the absolute benefit increased with increasing TlMl score. This indicates that although all categories of patients will benefit from clopidogrel, the greatest absolute benefit will be in high-risk subjects."

Two Circulation Editors Receive Gold Medal of the European Society of Cardiology
Hein J.J. Wellens, MD, Associate Editor of Circulation, and Attilio Maseri, MD, a Consulting Editor for the journal, received the Gold Medal of the European Society of Cardiology in ceremonies in Berlin, Germany, during the Society’s recent Congress.

Dr Wellens, one of the original investigators of clinical cardiac electrophysiology, unraveled the Wolff-Parkinson-White syndrome, and . . . [Full Text of this Article]